Clinical Trial Update: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

This clinical trial update notes the termination of a Phase 1 study of BDC-3042 as a single agent and in combination with cemiplimab in patients with multiple a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Colorectal Cancer
• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• BDC-3042
• Cemiplimab (cemiplimab)

Snippet

Sponsor: Bolt Biotherapeutics, Inc. | Conditions: Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma | Phase 1 | Status: TERMINATED